Category: Drug Safety Alerts
-
Natrecor “Dear Doctor” Letter Seeks to Address Recent Safety Concerns
Letter Includes New Natrecor Label Revised in April 2005 Natrecor is a treatment, administered by injection, for patients with acutely decompensated congestive heart failure (ADHF) with dyspnea. Recent reports in medical journals have raised…
-
Crestor Label Changes from March 2005 Not Posted on FDA MedWatch Site Until May 2005
Crestor Package Insert Label Changes Include Rhabdomyolysis Risk In March 2005 the FDA and AstraZeneca reached agreement about making certain changes to the package insert label for the pharmaceutical company’s cholesterol-lowering drug Crestor (rosuvastatin). …
-
Natrecor Linked to Increased Death Rates and Kidney Problems
Medical Journals Raised Questions about Safety of Natrecor Natrecor has been reported to increase kidney problems and death rates among patients in recent editions of Circulation and The Journal of the American Medical Association…
-
Trileptal Associated with Life-threatening Skin Reactions and Multi-organ Hypesensitivity: Health Canada Alert
Stevens Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) On April 28, 2005 Health Canada posted an alert on its web site concerning the association of Trileptal (oxcarbazepine), an anti-epileptic medication, with life-threatening dermatological…